| Identification | Back Directory | [Name]
6(5H)-Pteridinone, 7,8-dihydro-4,7,8-trimethyl-2-[[[1-[[6-(trifluoromethyl)-3-pyridinyl]methyl]-1H-pyrazol-4-yl]methyl]amino]-, (7S)- | [CAS]
2379577-82-7 | [Synonyms]
WSF1-IN-1
6(5H)-Pteridinone, 7,8-dihydro-4,7,8-trimethyl-2-[[[1-[[6-(trifluoromethyl)-3-pyridinyl]methyl]-1H-pyrazol-4-yl]methyl]amino]-, (7S)- | [Molecular Formula]
C20H21F3N8O | [MOL File]
2379577-82-7.mol | [Molecular Weight]
446.43 |
| Hazard Information | Back Directory | [Uses]
WSF1-IN-1 (compound 136), an orally active WSF1 inhibitor, can be used in the study for WSF1 (Wolfram syndrome) related tumors, with IC50 values of 0.33 μM and >27 μM in HepG2 parental and HepG2 WFS1 KO cell lines, respectively[1]. | [in vivo]
WSF1-IN-1 (compound 136, 100 mpk qd, orally, 14 days) exhibits 106.65% tumor growth inhibition (TGI) in NSCLC patient derived xenograft OD33996 nu/nu mice[1]. | [References]
[1] Lauffer, David J, et al. Preparation of pyridine compass. for the treatment of cellular proliferative disorders. US 20190322673 A1. |
|
|